INTRODUCTION: In this study we investigated the action of RAP-031, a soluble activin receptor type IIB (ActRIIB) comprised of a form of the ActRIIB extracellular domain linked to a murine Fc, and the NF-κB inhibitor, ursodeoxycholic acid (UDCA), on the whole body strength of mdx mice. METHODS: The whole body tension (WBT) method of assessing the forward pulling tension (FPT) exerted by dystrophic (mdx) mice was used. RESULTS: RAP-031 produced a 41% increase in body mass and a 42.5% increase in FPT without altering the FPT normalized for body mass (WBT). Coadministration of RAP-031 with UDCA produced increases in FPT that were associated with an increase in WBT. CONCLUSIONS: Myostatin inhibition increases muscle mass without altering the fundamental weakness characteristic of dystrophic muscle. Cotreatment with an NF-κB inhibitor potentiates the effects of myostatin inhibition in improving FPT in mdx mice.
INTRODUCTION: In this study we investigated the action of RAP-031, a soluble activin receptor type IIB (ActRIIB) comprised of a form of the ActRIIB extracellular domain linked to a murine Fc, and the NF-κB inhibitor, ursodeoxycholic acid (UDCA), on the whole body strength of mdxmice. METHODS: The whole body tension (WBT) method of assessing the forward pulling tension (FPT) exerted by dystrophic (mdx) mice was used. RESULTS:RAP-031 produced a 41% increase in body mass and a 42.5% increase in FPT without altering the FPT normalized for body mass (WBT). Coadministration of RAP-031 with UDCA produced increases in FPT that were associated with an increase in WBT. CONCLUSIONS:Myostatin inhibition increases muscle mass without altering the fundamental weakness characteristic of dystrophic muscle. Cotreatment with an NF-κB inhibitor potentiates the effects of myostatin inhibition in improving FPT in mdxmice.
Authors: Swarnali Acharyya; S Armando Villalta; Nadine Bakkar; Tepmanas Bupha-Intr; Paul M L Janssen; Micheal Carathers; Zhi-Wei Li; Amer A Beg; Sankar Ghosh; Zarife Sahenk; Michael Weinstein; Katherine L Gardner; Jill A Rafael-Fortney; Michael Karin; James G Tidball; Albert S Baldwin; Denis C Guttridge Journal: J Clin Invest Date: 2007-03-22 Impact factor: 14.808
Authors: Ashley L Siegel; Cathy Bledsoe; Jesse Lavin; Francesca Gatti; Jonas Berge; Gregory Millman; Eric Turin; W Tyler Winders; John Rutter; Beniamino Palmeiri; C George Carlson Journal: Neuromuscul Disord Date: 2008-12-02 Impact factor: 4.296
Authors: Brett M Morrison; Jennifer L Lachey; Leigh C Warsing; Beverlie L Ting; Abigail E Pullen; Kathryn W Underwood; Ravindra Kumar; Dianne Sako; Asya Grinberg; Vicki Wong; Elizabeth Colantuoni; Jasbir S Seehra; Kathryn R Wagner Journal: Exp Neurol Date: 2009-03-11 Impact factor: 5.330
Authors: C George Carlson; John Rutter; Cathy Bledsoe; Rajvir Singh; Helena Hoff; Kay Bruemmer; Jenna Sesti; Francesca Gatti; Jonas Berge; Laura McCarthy Journal: J Neurosci Methods Date: 2009-11-14 Impact factor: 2.390
Authors: Yun-Sil Lee; Adam Lehar; Suzanne Sebald; Min Liu; Kayleigh A Swaggart; C Conover Talbot; Peter Pytel; Elisabeth R Barton; Elizabeth M McNally; Se-Jin Lee Journal: Hum Mol Genet Date: 2015-07-23 Impact factor: 6.150
Authors: Luigi Formicola; Alice Pannérec; Rosa Maria Correra; Barbara Gayraud-Morel; David Ollitrault; Vanessa Besson; Shahragim Tajbakhsh; Jennifer Lachey; Jasbir S Seehra; Giovanna Marazzi; David A Sassoon Journal: Front Physiol Date: 2018-05-24 Impact factor: 4.566